Highlights from ADA 84th Scientific Sessions
Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, FL, USA, taking place 21-24 June 2024!
Supported by an unrestricted educational grant from AstraZeneca, Lilly and Novo Nordisk.
Day 4
Vlado Perkovic
The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist – Once-Weekly Semaglutide and the FLOW Trial Results
Dianna Magliano
Keeping Up with Hollywood – Who Should Be Prioritized for New Antiobesity Medications?
Jane Speight
Advances Towards Beta Cell Therapy as a Potential Cure for Type 1 Diabetes
Dughyun Choi
SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea
Yong Ho Lee
SELECT Trial – New Looks at Glycemia, Inflammation, and Heart Failure
So-Hun Kim
THE STEP-HFpEF and STEP-HFpEF-DM Trials – Targeting Obesity to Treat Heart Failure
Day 3
Mikhail Kosiborod
THE STEP-HFpEF and STEP-HFpEF-DM Trials – Targeting Obesity to Treat Heart Failure
Beverly Tchang
Severe GLP-1RA Side Effects in Obesity Treatment – Fact or Fiction?
Ramzi Ajjan
New Technology – Equity and Access
Jerry Greenfield
Noninsulin Treatment for Type 1 Diabetes
Ramzi Ajjan
Systemic Medications for Diabetic Retinopathy – Protective and Risk Factors
Jennifer Snaith
Efficacy and Safety of Tirzepatide in Overweight and Obese Patients with Type 1 Diabetes
Ronald Ma
Heterogeneity of Diabetes – Pathophysiology to Global Considerations
Day 2
David Nathan
Newly-Diagnosed Type 2 Diabetes – What Should Be the Focus of Management in 2024?
Steven Kahn
SELECT Trial – New Looks at Glycemia, Inflammation, and Heart Failure
André Gustavo Daher Vianna
Once Weekly Insulins – Data Presented at ADA
Jonathan Shaw
ADA Diabetes Care Symposium – The Final Frontier – Implementing the Learning from Implementation Science
Roger Chen
GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting – To Stop or Not to Stop?
Jerry Greenfield
GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting – To Stop or Not to Stop?
Jonathan Shaw
Health Care Policy and Diabetes – How to Improve Population Health from Multiple Perspectives
Day 1
Sof Andrikopoulos
Welcome to ADA
Mark Cooper
Edwin Bierman Award Lecture—Diabetes and Cardiovascular Disease—The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications
Helen Tesfaye
The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk
Roger Chen
SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea
Mark Cooper
SGLT2 Inhibition Impact on Human Physiology
Ramzi Ajjan
CGM in Type 2 Diabetes – An Overview from the ADA
Day 4
Day 4 highlights will be available soon. Stay tuned!